Literature DB >> 9496153

Neuropeptides of the autonomic nervous system in Sjögren's syndrome.

N Santavirta1, Y T Konttinen, J Törnwall, M Segerberg, S Santavirta, M Matucci-Cerinic, H Björvell.   

Abstract

OBJECTIVE: To assess the activity level of the autonomic nervous system in Sjögren's syndrome (SS) and to correlate this with stress.
METHODS: Patients with SS (n = 12) and healthy controls (n = 10) were analysed for the content of vasoactive intestinal peptide (VIP) and neuropeptide Y (NPY) in their stimulated saliva by radioimmunoassays and for stress by the use of a modified Jenkins Activity Survey (JAS).
RESULTS: The data are expressed as median (interquartile range). Salivary VIP output (pg/min) and NPY output (pg/min) were high in SS compared with healthy controls (30.0 (15.6, 36.6) versus 12.3 (9.2, 24.0), p = 0.045, 4.8 (0.6, 24.1) versus 0.7 (0.0, 2.4), p = 0.038, respectively). Patients experienced only a little, but not significantly, more stress than the healthy controls (stress index -2.8 (-7.7, 6.9) versus -5.2 (-12.9, 2.7), p > 0.05). Stress in general was associated with high salivary VIP concentrations (r = 0.41, p = 0.05).
CONCLUSIONS: These findings show that adequately processed saliva (containing aprotinin and EDTA as neuropeptidase inhibitors) contains measurable amounts of marker peptides of the autonomic nervous system. Secondly, VIP concentration but not output may be affected by stress, which may act by decreasing watery salivary flow. In patients with SS, VIP and NPY outputs are increased. This may indicate increased leakage into saliva or efforts to compensate for the diminished salivary flow, or both.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9496153      PMCID: PMC1752311          DOI: 10.1136/ard.56.12.737

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  The Copenhagen criteria for Sjögren's syndrome.

Authors:  R Manthorpe; P Oxholm; J U Prause; M Schiødt
Journal:  Scand J Rheumatol Suppl       Date:  1986

2.  VIP in salivary glands in Sjögren's syndrome.

Authors:  J Törnwall; Y T Konttinen; J Hietanen; T Sorsa; M Hukkanen; H Uusitalo
Journal:  Br J Rheumatol       Date:  1995-09

3.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; G Balestrieri; W Bencivelli; R M Bernstein; K B Bjerrum; S Braga; J Coll; S de Vita
Journal:  Arthritis Rheum       Date:  1993-03

Review 4.  Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain.

Authors:  Y T Konttinen; P Kemppinen; M Segerberg; M Hukkanen; R Rees; S Santavirta; T Sorsa; A Pertovaara; J M Polak
Journal:  Arthritis Rheum       Date:  1994-07

5.  Role of nitric oxide in Sjögren's syndrome.

Authors:  Y T Konttinen; L A Platts; S Tuominen; K K Eklund; N Santavirta; J Törnwall; T Sorsa; M Hukkanen; J M Polak
Journal:  Arthritis Rheum       Date:  1997-05

6.  Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia).

Authors:  P C Fox; J C Atkinson; A A Macynski; A Wolff; D S Kung; I H Valdez; W Jackson; R A Delapenha; J Shiroky; B J Baum
Journal:  Arch Intern Med       Date:  1991-06

7.  Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer.

Authors:  J T Johnson; G A Ferretti; W J Nethery; I H Valdez; P C Fox; D Ng; C C Muscoplat; S C Gallagher
Journal:  N Engl J Med       Date:  1993-08-05       Impact factor: 91.245

8.  Effectiveness of pilocarpine in postradiation xerostomia.

Authors:  D Greenspan; T E Daniels
Journal:  Cancer       Date:  1987-03-15       Impact factor: 6.860

9.  Peptide-containing nerves in labial salivary glands in Sjögren's syndrome.

Authors:  Y T Konttinen; M Hukkanen; P Kemppinen; M Segerberg; T Sorsa; M Malmström; S Rose; S Itescu; J M Polak
Journal:  Arthritis Rheum       Date:  1992-07

10.  The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A placebo controlled study.

Authors:  N Talal; J H Quinn; T E Daniels
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

View more
  11 in total

1.  Different effects of steroidal therapy on neuropeptide-active enzymes in male and female human saliva.

Authors:  Federica Albo; Riccardo Antonangeli; Antonella Cavazza; Mario Marini; L Giorgio Roda; Paolo Rossi
Journal:  Neurochem Res       Date:  2002-09       Impact factor: 3.996

Review 2.  Incorporating salivary biomarkers into nursing research: an overview and review of best practices.

Authors:  Douglas A Granger; Sara B Johnson; Sarah L Szanton; Dorothée Out; Lynette Lau Schumann
Journal:  Biol Res Nurs       Date:  2012-05-15       Impact factor: 2.522

3.  Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

Authors:  M Matucci-Cerinic; R Giacomelli; A Pignone; M L Cagnoni; S Generini; R Casale; P Cipriani; A Del Rosso; P Tirassa; Y T Konttinen; B M Kahaleh; P S Fan; M Paoletti; C Marchesi; M Cagnoni; L Aloe
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

4.  Impaired microvascular response to cholinergic stimuli in primary Sjögren's syndrome.

Authors:  L Kovács; T Török; F Bari; Z Kéri; A Kovács; E Makula; G Pokorny
Journal:  Ann Rheum Dis       Date:  2000-01       Impact factor: 19.103

5.  Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome.

Authors:  B M Lodde; F Mineshiba; J Wang; A P Cotrim; S Afione; P P Tak; B J Baum
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

6.  Abnormal autonomic cardiovascular control in ankylosing spondylitis.

Authors:  E Toussirot; M Bahjaoui-Bouhaddi; J C Poncet; S Cappelle; M T Henriet; D Wendling; J Regnard
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

7.  The Role of Salivary Neuropeptides in Pediatrics: Potential Biomarkers for Integrated Therapies.

Authors:  Lynn A Gershan; Paul L Durham; Jaci Skidmore; Joshua Shimizu; Ryan J Cady; Xiaoming Sheng; Christopher G Maloney
Journal:  Eur J Integr Med       Date:  2015-08       Impact factor: 1.314

8.  Chronic inflammation enhances NGF-β/TrkA system expression via EGFR/MEK/ERK pathway activation in Sjögren's syndrome.

Authors:  Sabrina Lisi; Margherita Sisto; Domenico Ribatti; Massimo D'Amore; Raffella De Lucro; Maria Antonia Frassanito; Loredana Lorusso; Angelo Vacca; Dario Domenico Lofrumento
Journal:  J Mol Med (Berl)       Date:  2014-02-21       Impact factor: 4.599

Review 9.  Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2011-06-01

10.  Impaired vascular responses to parasympathetic nerve stimulation and muscarinic receptor activation in the submandibular gland in nonobese diabetic mice.

Authors:  Ellen Berggreen; Krister Nyløkken; Nicolas Delaleu; Hamijeta Hajdaragic-Ibricevic; Malin V Jonsson
Journal:  Arthritis Res Ther       Date:  2009-02-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.